HIV-1/HIV-2 IgG Antibodies. Screening

Clinical information

Diagnostic Utility:

This is the qualitative detection of IgG antibodies against HIV-1/HIV-2 virus and its determination is useful in:

• Identification of individuals with HIV-1/HIV-2 infection.
• Blood component transfusion.
• Transplantation of progenitor cells, solid organs, and tissues.
• Screening for infectious diseases in egg and semen donors.

Method:

Chemiluminescence Immunoassay (ChLIA).

Reference Values

Possible results are: Reactive and Non-Reactive.

Diagnostic Algorithm:

In case of reactive HIV-1/HIV-2 anti-IgG result, the confirmatory HIV-1/HIV-2 antibody test by Immunoblot can be requested:

(*) Only carried out upon request.

Response Time:

Maximum 2 working days

Specimen information

Sample: Serum and/or plasma
Tube: Aliquots of 1-5 mL, plasma tubes with EDTA, potassium oxalate, sodium citrate, ACD, CP2D, CPD, or CPDA-1 as anticoagulant and/or serum tubes with and without gel separator.
Minimum essential volume: 1 ml
Stability:

• At room temperature: ≤ 4 days
• In refrigeration 2-8 ºC: ≤ 14 days
• Sample frozen at or below -20ºC: 10 years

Transport instructions: Preferably at room temperature and/or refrigerated if they are whole blood tubes, and frozen if they are serum and/or plasma aliquots.

Reason for rejection: Sample highly hemolyzed.

Administrative information

BST Code: 0111
Test Description: HIV-1/HIV-2, IgG Antibodies. Screening
Synonyms: anti-HIV-1/HIV-2
Section: Transfusion Safety Laboratory
BST Rate: Check the updated rates here.

Profiles:

The test 0111 HIV-1/HIV-2, IgG Antibodies. Screening can be requested alone or with the profile:

References

• Inserts kits test ABBOTT PRISM HIV O PLUS

Quality

BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.